Neurogene (NGNE) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

NGNE Neurogene

Watchlist

41.950
+1.590+3.94%

Close Sep 13 16:00 ET

41.950
0.0000.00%

Post 16:01 ET

545.08MMarket Cap-14812P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Neurogene's (NASDAQ:NGNE) Earnings Might Be Weaker Than You Think
Yahoo FinanceAug 17 10:01 ET
BMO Capital Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $65
Moomoo NewsAug 14 07:34 ET · Ratings
Buy Rating for Neurogene: Promising Rett Syndrome Program and Strong Financial Outlook
TipRanksAug 14 07:25 ET · Ratings
Buy Rating Affirmed for Neurogene Amid Promising Outlook for Gene Therapy Candidate NGN-401
TipRanksAug 13 09:49 ET · Ratings
Neurogene's NGN-401 Wins Key FDA Designation
TipRanksAug 12 09:43 ET
Neurogene's NGN-401 Shows Promise for Rett Syndrome
TipRanksAug 12 09:43 ET

Comments

Jaguar8

Apr 22 15:37

$Neurogene (NGNE.US)$
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

NGNE Neurogene

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target